BPIQ Blog

Summary: The TVTX PDUFA for Sparsentan is coming up on February 17 for IgA Nephropathy (IgAN) The market reacted positively when Phase 3...

We're coming to the end of January as we set our sights on Feb and the remaining Q1 events. We have a number of readouts coming including...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13 This conference will focus on genitourinary cancers...

Summary: GTHX Trilaciclib Phase 3 data in colorectal cancer is expected in February 2023 This is initial PRESERVE 1 CRC data and initial...

Originally posted 1/25/23; last updated 4/13/23 Summary: Many exciting Alzheimer's disease catalysts are coming throughout the year See...

Summary: SAVA Ph2 Open label study topline data was reported today, 1/24/23 While the data was reported as positive, the market did not...

SUMMARY Yesterday, AGEN presented updated data on its lead candidate, an anti-CTLA-4 at ASCO-GI23 The AGEN ASCO-GI23 presentation...

This weekend we have the ASCO-GI biomedical meeting happening with some new data coming. See our full ASCO-GI post with catalyst...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...